Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ADGI

Adagio Therapeutics (ADGI) Stock Price, News & Analysis

Adagio Therapeutics logo

About Adagio Therapeutics Stock (NASDAQ:ADGI)

Key Stats

Today's Range
N/A
50-Day Range
$3.40
$4.78
52-Week Range
N/A
Volume
22,357 shs
Average Volume
2.27 million shs
Market Capitalization
$504.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Receive ADGI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADGI Stock News Headlines

Our Favorite Advent Calendars
Top secret Trump trades?
As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”
See More Headlines

ADGI Stock Analysis - Frequently Asked Questions

Adagio Therapeutics, Inc. (NASDAQ:ADGI) released its earnings results on Sunday, November, 14th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $0.24.

Adagio Therapeutics (ADGI) raised $301 million in an initial public offering on Friday, August 6th 2021. The company issued 17,700,000 shares at $16.00-$18.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adagio Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Pfizer (PFE), PayPal (PYPL), Tesla (TSLA), AbbVie (ABBV) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/14/2021
Today
11/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ADGI
Fax
N/A
Employees
2,021
Year Founded
N/A

Profitability

Net Income
$-226,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.02 per share

Miscellaneous

Free Float
N/A
Market Cap
$504.98 million
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:ADGI) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners